U.S., Feb. 20 -- ClinicalTrials.gov registry received information related to the study (NCT06835595) titled 'TMS-related Measures As Biomarker of Cognitive Impairment in PD' on Feb. 14.
Brief Summary: The goal of the present study is to explore the diagnostic and prognostic value of neurophysiological biomarkers obtained through paired-pulse Transcranial Magnetic Stimulation (TMS) techniques in individuals affected by Parkinson's disease (PD) with and without cognitive decline.
The main questions it aims to answer are:
* TMS measures of cortical excitability are able to distinguish between PD patients cognitively normal, PD-Mild Cognitive Impairment (PD-MCI) and PD-Dementia (PD-D)?
* TMS measures of cortical excitability are able to pre...